We use cookies to ensure that we give you the best experience on our website Learn more

Oct 29, 2018

7th Congress of the European Academy of Paediatric Societies

0337 - FEASIBILITY OF CELL THERAPY FOR NEONATES WITH HYPOXIC ISCHEMIC ENCEPHALOPATHY

hypoxic ischemic encephalopathy

cerebral palsy

therapeutic hypothermia

cord blood stem cells

mesenchymal stromal cells

regenerative therapy

Abstract

Abstract

thumbnail

Keywords

hypoxic ischemic encephalopathy

cerebral palsy

therapeutic hypothermia

cord blood stem cells

mesenchymal stromal cells

regenerative therapy

Abstract

Background and aims Hypoxic ischemic encephalopathy (HIE) is considered to be a major cause of cerebral palsy (CP). Therapeutic hypothermia (TH) has been the only effective treatment for HIE to prevent the development of CP. However, even if infants are treated with TH, nearly half of them die or left with moderate to severe neurological impairments as yet. A recent publication indicated benefits of regenerative medicine by cord blood stem cells (CBS) or mesenchymal stromal cells (MSC) which is expected as a remarkable excellent therapeutic method as a treatment for HIE. We studied feasibility of CBS and MSC for neonates with HIE. Methods: CBS was collected aseptically and prepared by using SEPAX. MSC were collected aseptically and isolated from umbilical cord (UC), and cryopreserved after culture. Infants admitted to the NICU of 6 hospitals in our research group will be eligible if they are ≥36 weeks’ gestational age and birth weight ≥1800 g with HIE and meet the cooling criteria. Results: CBS therapy for neonatal HIE in addition to TH was performed in 6 newborn patients. All of them have discharged NICU without support of ventilator and survived from 1 to 3 years. UC-MSC have been defined and characterized as ease of collection, storage, and transport, and low immunogenicity with significant immunosuppressive ability. Conclusions: Autologous CBS for newborn HIE is safe and feasible, and warrants a larger and controlled phase II study in Japan. UC-MSC therapy will give the possibility of treatment to patients who could not get CBS.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.